| abstract |
The invention provides a medicinal composition which functions to activate soluble guanylate cyclase (sGC) and which is for the treatment or prevention of various cardiovascular diseases that is based on an improvement in cGMP signals. An imidazo[1,2-a]pyridine compound represented by formula (I), which has a carbamoyl group at the 3-position of the imidazo[1,2-a]pyridine framework and has a specific ring group bonded to the 8-position through a methyleneoxy group, or a salt of the compound. The pyridine compound or salt functions to activate sGC and is useful as the active ingredient of a medicinal composition for the treatment or prevention of various cardiovascular diseases in which sGC participates, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension. In formula (I), A<1> is cyclohexyl, phenyl substituted by 1-3 fluorine atoms, or 3-fluoropyridin-2-yl and R is a group represented by any of the formulae (i) to (vii). |